[1] Acres B,Limacher JM.MUC1 as a target antigen for cancer immunotherapy[J]. Expert Rev Vaccines,2005,4(4):493-502.
[2] Nath S,Mukherjee P. MUC1:a multifaceted oncoprotein with a key role in cancer progression[J].Trends Mol Med,2014,20(6):332-342.
[3] Vassilaros S,Tsibanis A,Tsikkinis A,et al.Up to 15-year clinical follow-up of a pilot phase Ⅲ immunotherapy study in stage Ⅱ breast cancer patients using oxidized mannan-MUC1[J].Immunotherapy,2013,5(11):1177-1182.
[4] Quoix E,Ramlau R,Westeel V,et al.Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer:a controlled phase 2B trial[J].Lancet Oncol,2011,12(12):1125-1133.
[5] Wurz GT,Kao CJ,Wolf M,et al.Tecemotide:An antigen-specific human vaccines &immunotherapeutics[J].Cancer Immunother,201410(11):3383-3393.
[6] Fang F,Ma J,Ni W,et al.MUC1 and maltose-binding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice[J].Mol Med Rep,2014,7(10):1056-1064.
[7] Hu B,Wang J,Guo Y,et al.Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine[J].Int Immunopharmacol,2016,33:108-118.
[8] Wille-Reece U,Flynn BJ,Loré K,et al.Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates[J].J Exp Med,2006,203(5):1249-1258.
[9] Steinhagen F,Kinjo T,Bode C,et al.TLR-based immune adjuvants[J].Vaccine,2011,29(17):3341-3355.
[10] Girart MV,Fuertes MB,Domaica CI,et al.Engagement of TLR3,TLR7,and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12[J].J Immunol,2007,179(6):3472-3479.
[11] 方芳.重组MUC1-MBP融合蛋白疫苗抗肿瘤作用机制研究[D].长春:吉林大学,2010.
[12] 孙霞霞.不同佐剂对重组MUC1-MBP融合蛋白诱导的免疫活性的影响[D].长春:吉林大学,2013.
[13] Fujita Y,Hirai K,Nishida K,et al.6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine:Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine[J].Amino Acids,2016,48(5):1319-1329.
[14] Smith AJ,Li Y,Bazin HG,et al.Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants[J].Vaccine,2016,34(36):4304-4312.
[15] Wang Y,Chen K,Wu Z,et al.Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice[J].Int J Infect Dis,2014,12(29):31-36.
[16] 尹凌凡,范艳莹,李丽,等.Toll样配体(R-848)与IL-12对人NK细胞亚群IFN-γ产生的作用[J].细胞与分子免疫学杂志,2007,23(7):623-626.
[17] 范艳莹,付笑迎,尹凌凡,等.TLR7/8配体(R848)对人NK细胞杀伤功能的作用及其机制的探讨[J].免疫学杂志,2010,26(8):657-660. |